Alzheimer’s Therapeutics Market: Global Industry Analysis and Forecast (2022-2029) by Therapeutics, Diagnostics, End-user, and Region

Alzheimer’s Therapeutics Market size was valued at USD 4.5 Bn. in 2021 and the total Alzheimer’s Therapeutics revenue is expected to grow at a CAGR of 19.3% from 2022 to 2029, reaching nearly USD 18.46 Bn.

Alzheimer’s Therapeutics Market Overview:

Alzheimer's disease (AD) is a neurodegenerative disorder that damages the brain's nerve cells or neurons, resulting in memory loss, thinking and language difficulties, and behavioural abnormalities. The number of individuals living with Alzheimer's disease is rapidly increasing, yet only around one in every four persons with the condition gets identified. The increased prevalence of Alzheimer's disease, as well as the approval of disease-modifying medicines, are expected to drive Alzheimer’s Therapeutics Market growth. According to the NCBI, over 6.2 million Americans aged 65 and up were diagnosed with Alzheimer's disease in 2021, with the number expected to rise to around 13.8 million by 2060. Women are more prone to be diagnosed with Alzheimer’s disease than men due to the longer life expectancy of women. Additionally, Alzheimer's disease is rapidly becoming the leading cause of mortality in neurodegenerative disorders, as well as a leading source of physical disorders which need rapid treatment. The increasing use of biomarkers in Alzheimer's diagnosis and medication development, as well as the rising incidence of Alzheimer's disease globally, are the primary drivers driving the growth of the Alzheimer's therapeutics market. According to the World Health Organization's September 2021 report, around 55 million people around the world with dementia, with nearly 10 million cases recorded each year. Alzheimer's is the most frequent kind of dementia, accounting for 60-70% of all dementia cases. With the increasing incidence of Alzheimer's disease around the world, governments and non-governmental organizations are spending significantly on the development of diagnostics and therapeutics for the condition, which may increase market growth. The Alzheimer's Drug Discovery Foundation (ADDF) Diagnostics Accelerator, for example, unveiled four new research investments in June 2021 for the creation of digital biomarkers for Alzheimer's diagnosis. Such investments are expected to drive global Alzheimer’s Therapeutics market growth during the forecast period. Besides that, with advancements in diagnostic technologies and ongoing research activities in the field, businesses are increasing their product offerings and launching new products, which, along with other business expansion initiatives such as mergers and acquisitions, strategic collaboration, and new investments into other companies, are expected to supplement the growth of the Alzheimer's therapeutics market during the forecast period. For example, in August 2019, Oxford Brain Diagnostics (an Oxford University spinoff) released a novel approach for identifying Alzheimer's disease using MRI images. However, high failure rates in clinical trials linked to diagnosis and treatment, as well as difficulties in early Alzheimer's diagnoses, are expected to restrict the growth of the Alzheimer's therapeutics market during the forecast period. Alzheimer’s Therapeutics Market To know about the Research Methodology:- Request Free Sample Report

Alzheimer’s Therapeutics Market Dynamics:

High adoption of Biomarkers in Diagnosis and Drug Development to drive Alzheimer’s Therapeutics Market The development of novel diagnostic procedures is becoming increasingly critical to enhancing precision in early Alzheimer's disease (AD) diagnosis. As a result, biomarkers are being studied in order to improve the efficacy of diagnosis. Biomarkers are neurochemical signs that are used to identify illness risk or occurrence. These biomarkers can be utilized in a variety of medication development procedures; however, they are most typically used as supplementary diagnostic measures for the clinical diagnosis of Alzheimer's disease. Several biomarkers are used to detect different stages of Alzheimer's disease. Examples include beta-amyloid and tau levels in CSF fluid and imaging-detectable brain abnormalities. Data from various clinical studies have shown that the basic AD cerebrospinal fluid (CSF) biomarkers, such as amyloid- (A42), total tau (T-tau), and phosphorylated tau (P-tau), represent important aspects of AD pathology. As a result, biomarkers are increasingly being utilized in drug research to increase the success rate and cost-effectiveness of rational drug development. A huge number of clinical investigations have repeatedly demonstrated that these biomarkers can provide diagnostically useful information in the early stages of the disease. Additionally, recent technological advancements in fully automated assays have made it possible to test these biomarkers with great accuracy and stability. Microtubule-binding region tau (MTBR tau) was discovered in the fluid surrounding the brain and spinal cord by scientists at Washington University School of Medicine in Missouri in 2020. Doctors would be able to quantify tau protein levels using this MTBR tau fluid biomarker, allowing them to assess the stage of the illness without the requirement for a brain scan, and it might be used to screen patients before they show indications of cognitive deterioration. These are expected to impact the development of more effective diagnostic procedures and may aid in the improvement of treatment outcomes. According to a study published in the Journal of Alzheimer's and Dementia (2020) titled "Alzheimer's Disease Biomarker Roadmap 2020: Fluid Biomarkers," the key cerebrospinal fluid (CSF) AD biomarkers (t-tau, p-tau181, and A) have the greatest degree of maturity for clinical application. Blood indicators for p-tau18, and to a lesser extent A, diagnose AD better than non-AD neurodegenerative disorders. In addition, the increasing investments in biomarkers for drug development and early detection of AD can lead to higher adoption rates of biomarker-based diagnostics and the development of new therapeutics. This is expected to drive the global growth of the Alzheimer's therapeutics market during the forecast period. A Large Number of Drugs in The Pipeline Alzheimer’s disease (AD) has been becoming a major threat to public health, due to the increasing number of infected persons. According to the Alzheimer's Association Report, around 121,499 AD deaths were registered in the United States in 2019. As a result, Alzheimer's disease is the sixth-leading cause of mortality in the United States, and the fifth-leading cause of death for people 65 and older. As the number of individuals suffering from Alzheimer's disease and mortality related to the condition rises, new medicines for the disease's detection and treatment are desperately needed. According to the Alzheimer's Association, if the illness's beginning is delayed by five years, the prevalence of the condition can be reduced by half. Many pipeline medications function through neurotransmitter systems to improve cognition or regulate neuropsychiatric disorders. However, some of these pipeline compounds are aimed toward disease-modifying medicines, which prevent, postpone, or reduce the course of Alzheimer's disease and solely target the underlying pathophysiologic pathways. The Alzheimer's Association awarded ImmunoBrain Checkpoint Inc. a USD 1,000,000 grant in October 2020 to support the Phase 1 clinical study for "IBC-Ab002" in the treatment of Alzheimer's. This is expected to drive Alzheimer's therapeutics market growth. Razadyne (galantamine); Exelon (rivastigmine); Aricept (donepezil); Namenda (memantine); Namzaric (memantine + donepezil); and Cognex are the six medications licensed to treat Alzheimer's disease by increasing the number of neurotransmitters. Cognex (tacrine) has been withdrawn since 2013, and generics for every other authorized API are now available. The National Institute on Aging (NIA) provided money in 2019 to establish the NIA Imbedded Pragmatic AD/ADRD Clinical Trials (IMPACT) Collaboratory. The Collaboratory may support pilot trials to test non-drug, care-based therapies for persons living with dementia. This would comprise professionals from more than 30 academic institutes. However, a huge number of medications in the pipeline for Alzheimer's disease treatment have been directly driving the global growth of the Alzheimer's therapeutics market, and the introduction of a new drug might result in strong growth of the Alzheimer's therapeutics market. Alzheimer’s Therapeutics MarketHigh Failure Rates of Late-Stage Drugs The increasing number of disease-modifying drugs in the early stages of trials suggests that the industry is more focused on developing blockbuster products that can cure the disease; however, a decreasing proportion of disease-modifying therapies in later phases suggests that trial failure rates are significantly higher, particularly for disease-modifying drugs. Eli Lilly and Company stated in February 2020 that the analysis undertaken by the Washington University School of Medicine in the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Study revealed that solanezumab did not reach the main objective. as a result, the company announced that it did not plan to pursue a submission for solanezumab in people with dominantly inherited Alzheimer's disease (DIAD), also known as autosomal dominant Alzheimer's disease, based on the result of the primary endpoint. Besides, smaller biotech companies, huge pharmaceutical corporations have also experienced multiple failures in late-phase clinical studies. For example, in 2019, Biogen and Eisai Co. Ltd announced the cancellation of the global Phase 3 studies ENGAGE and EMERGE, which were meant to assess the effectiveness and safety of aducanumab in patients with moderate cognitive impairment attributable to Alzheimer's disease and mild Alzheimer's disease dementia. The trials were discontinued due to the findings of a futility study undertaken by an independent data monitoring committee, which revealed that the trials were unlikely to reach their main aim upon completion. As a result, the failure of these late-stage medications has significantly hampered the global growth of the Alzheimer's therapeutics market.

Alzheimer’s Therapeutics Market Segment Analysis:

Based on Therapeutics, the Cholinesterase inhibitors segment held the largest market share of about 68% and dominated the Alzheimer’s Therapeutics market in 2021. The segment is further expected to grow at a CAGR of about 19.2% and maintain its dominance at the end of the forecast period. Cholinesterase inhibitors, commonly known as acetylcholinesterase inhibitors, are a type of medication that prevents the natural breakdown of acetylcholine, a neurotransmitter. Cholinesterase inhibitors suppress the enzyme cholinesterase, which is responsible for the breakdown of acetylcholine neurotransmitters in the body. Cholinesterase inhibitors are routinely recommended to treat symptoms linked to memory, thinking, language, judgment, and other mental processes because they have been shown to modestly slow the loss of brain function in persons suffering from mild to moderate Alzheimer's disease. The most common cholinesterase inhibitor medications on the market nowadays are donepezil, galantamine, rivastigmine, and memantine. Alzheimer’s Therapeutics MarketNowadays, cholinesterase inhibitors are the major drugs available for Alzheimer’s disease in the market because the enzyme cholinesterase is a significant therapeutic target for Alzheimer's. As a result, as a number of pharmaceutical organizations focus on developing Alzheimer's therapies based on cholinesterase inhibitors, the segment is expected to grow throughout the forecast period. For example, in October 2021, Corium Inc. obtained a target action date of March 11, 2022, from the United States Food and Drug Administration for its new drug application (NDA) for once-weekly ADLARITY (donepezil transdermal system) for the treatment of Alzheimer's patients. Donepezil is the most often prescribed Alzheimer's treatment in a family called cholinesterase inhibitors. These New advancements are expected to drive the segment's growth during the forecast period. Besides that, during the COVID-19 outbreak, cholinesterase was intensively examined for its safety, effectiveness, and side effects in Alzheimer's patients with COVID-19 infection, which is expected to influence the segment's growth as COVID-19 cases increase globally. For example, in the study "Potential Novel Role of COVID-19 in Alzheimer's Disease and Preventative Mitigation Strategies," published in June 2020, the cholinergic anti-inflammatory pathway was found to be a viable target for controlling inflammation and preventing cytokine storm in Alzheimer's patients after COVID-19 virus infection was detected. According to the same study, acetylcholinesterase inhibitors might be used as an additional treatment. As a result, COVID-19 is expected to have an impact on the growth of the cholinesterase inhibitors segment throughout the forecast period. The pipeline's drugs segment is expected to grow at a CAGR of about 18.2% during the forecast period. The impending release of many disease-modifying medicines into the market is expected to drive segment growth during the forecast period. Major Organizations such as F. Hoffmann-La Roche Ltd., Biogen/Eisai Inc., and Eli Lilly and Company are developing medication candidates that could change the therapeutic landscape for Alzheimer's disease. According to the Alzheimer's Association, 143 medication candidates were in 172 research studies for Alzheimer's disease. Thirty-one medication candidates were in phase 3 clinical trials, 82 were in phase 2, and 30 were in phase 1. The successful conclusion of studies and subsequent approval of these medications is expected to drive the growth of the Alzheimer's Therapeutics market.

Alzheimer’s Therapeutics Market Regional Insights:

North America held the largest market share of about 38% and dominated the market in 2021. The region is expected to grow at a CAGR of about 18.9% and maintain its dominance at the end of the forecast period. The high prevalence of Alzheimer's disease and the region's aging population, as well as significant investment in research & development activities and the launch of new products, are expected to be the primary growth drivers for the North American Alzheimer's Therapeutics market. For example, the Chief Science Officer of the Alzheimer's Society of Canada indicated in an interview in June 2021 that "during the next ten years, it's predicted that more than one million individuals in Canada will be living with dementia." This indicates that the increase in the prevalence of Alzheimer’s in the North American region is expected to rise the demand for diagnostic and therapeutic products for Alzheimer’s, which may drive Alzheimer’s Therapeutics market growth during the forecast period. However, the region's aging population is expected to increase the prevalence of Alzheimer's disease, as the geriatric population is more vulnerable to neurodegenerative disorders like Alzheimer's because it is an age-related disease. According to the United Nations' World Population Ageing Highlight report for 2019, the US geriatric (aged 65 and up) population was 53,340,00 in 2019, 6,602,000 in Canada, and 9,462,000 in Mexico, and by 2050, it is expected to rise to 26,416,000 in Mexico, 11,436,000 in Canada, and 84,813,000 in the United States. The United States is expected to grow at a CAGR of about 18.8% and hold a major market share of the North American Alzheimer’s Therapeutics market during the forecast period. The high prevalence of Alzheimer’s disease amongst the U.S. population, new product launches by key competitiors, the growing geriatric population, and the presence of robust healthcare infrastructure for Alzheimer’s detection and therapeutics are expected to drive the U.S. Alzheimer’s therapeutics market. According to the Alzheimer's Association's March 2021 study, roughly 6.2 million individuals aged 65 and older in the United States are living with Alzheimer's-related dementia, with this figure expected to rise to 13.8 million by 2060. Alzheimer’s Therapeutics MarketIn addition, Alzheimer's and dementia-related fatalities increased by 16% in the United States during the COVID-19 outbreak. It is stated that the government spends around USD 355 billion on Alzheimer's and other dementia-related costs in 2021, with this figure expected to climb to more than USD 1.1 trillion by 2050. The Alzheimer's Association numbers not only illustrate the disease's high frequency in the United States but also the financial effect on the country's economy. As a result, demand for Alzheimer's diagnosis and treatment is expected to increase substantially in the country, potentially boosting the Alzheimer’s Therapeutics market. Rising number of research studies related to the diagnostics and therapeutics of Alzheimer's disease, as well as significant government and private sector investment in the country, the market in the United States is expected to grow during the forecast period. For example, the United States Congress increased Alzheimer's and dementia research funding at the National Institute of Health (NIH) by USD 300 million in December 2020, including USD 15 million to fund and implement the Building Our Largest Dementia (BOLD) Infrastructure for Alzheimer's Act and advances in the Improving HOPE for Alzheimer's Act for FY 2021. These factors are expected to drive the Alzheimer’s Therapeutics market growth during the forecast period.

Alzheimer’s Therapeutics MarketAlzheimer’s Therapeutics Market Scope: Inquire before buying

Alzheimer’s Therapeutics Market
Report Coverage Details
Base Year: 2021 Forecast Period: 2022-2029
Historical Data: 2017 to 2021 Market Size in 2021: US $ 4.5 Bn.
Forecast Period 2022 to 2029 CAGR: 19.3% Market Size in 2029: US $ 18.46 Bn.
Segments Covered: by Therapeutics • Cholinesterase Inhibitors • NMDA Receptor Antagonist • Combination Drug • Pipeline Drugs
by Diagnostics • Brain Imaging • CFS Test for Alzheimer's Disease
by End-user • Hospital Pharmacy • Retail Pharmacy • E-commerce

Alzheimer’s Therapeutics Market, by Region

• North America • Europe • Asia Pacific • Middle East and Africa • South America

Alzheimer’s Therapeutics Market Key Players are:

Hoffmann-La Roche • Novartis AG • Bristol-Myers Squibb • AstraZeneca PLC • Corium Inc. • Eisai Co. Ltd. • H. Lundbeck A/S • AC Immune • Biogen Inc. • Johnson & Johnson • Eli Lilly and Company • Lupin Limited • Daiichi Sankyo Company, Limited • TauRx Pharmaceuticals Ltd. • AbbVie Inc. • Siemens Healthineers • Zydus Cadila • Merz Pharma • Teva Pharmaceutical Industries Ltd • Adamas Pharmaceuticals Inc. • Aurobindo Pharma Ltd • Cipla Ltd. • Torrent pharmaceuticals ltd. • Lannett Inc. • Unichem laboratories ltd. FAQs: 1. What are the growth drivers for the Alzheimer’s Therapeutics market? Ans. The increasing automotive sector, increasing commercialization, growing building activity, rapidly changing customer preferences for customized automobiles, as well as increased demand for lightweight and fuel-efficient vehicles, are expected to be the major driver for the Alzheimer’s Therapeutics market. 2. What is the major restraint for the Alzheimer’s Therapeutics market growth? Ans. The Stringent Regulations on Alzheimer’s Therapeutics adoption are expected to be the major restraining factor for the Alzheimer’s Therapeutics market growth. 3. Which region is expected to lead the global Alzheimer’s Therapeutics market during the forecast period? Ans. The Asia-Pacific market is expected to lead the global Alzheimer’s Therapeutics market during the forecast period due to the increased number of production plants in the Asia-Pacific region increasing the demand for Alzheimer’s Therapeutics products and eventually driving the market growth. 4. What is the projected market size & growth rate of the Alzheimer’s Therapeutics Market? Ans. The Alzheimer’s Therapeutics Market size was valued at USD 4.5 Bn. in 2021 and the total Alzheimer’s Therapeutics revenue is expected to grow at a CAGR of 19.3% from 2022 to 2029, reaching nearly USD 18.46 Bn. 5. What segments are covered in the Alzheimer’s Therapeutics Market report? Ans. The segments covered in the Alzheimer’s Therapeutics market report are Therapeutics, Diagnostics, End-user, and Region.
1. Global Alzheimer’s Therapeutics Market: Research Methodology 2. Global Alzheimer’s Therapeutics Market: Executive Summary 2.1 Market Overview and Definitions 2.1.1. Introduction to Global Alzheimer’s Therapeutics Market 2.2. Summary 2.2.1. Key Findings 2.2.2. Recommendations for Investors 2.2.3. Recommendations for Market Leaders 2.2.4. Recommendations for New Market Entry 3. Global Alzheimer’s Therapeutics Market: Competitive Analysis 3.1 MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2 Consolidation in the Market 3.2.1 M&A by region 3.3 Key Developments by Companies 3.4 Market Drivers 3.5 Market Restraints 3.6 Market Opportunities 3.7 Market Challenges 3.8 Market Dynamics 3.9 PORTERS Five Forces Analysis 3.10 PESTLE 3.11 Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • South America 3.12 COVID-19 Impact 4. Global Alzheimer’s Therapeutics Market Segmentation 4.1 Global Alzheimer’s Therapeutics Market, by Therapeutics (2021-2029) • Cholinesterase Inhibitors • NMDA Receptor Antagonist • Combination Drug • Pipeline Drugs 4.2 Global Alzheimer’s Therapeutics Market, by Diagnostics (2021-2029) • Brain Imaging • CFS Test for Alzheimer's Disease 4.3 Global Alzheimer’s Therapeutics Market, by End-user (2021-2029) • Hospital Pharmacy • Retail Pharmacy • E-commerce 5. North America Alzheimer’s Therapeutics Market(2021-2029) 5.1 North America Alzheimer’s Therapeutics Market, by Therapeutics (2021-2029) • Cholinesterase Inhibitors • NMDA Receptor Antagonist • Combination Drug • Pipeline Drugs 5.2 North America Alzheimer’s Therapeutics Market, by Diagnostics (2021-2029) • Brain Imaging • CFS Test for Alzheimer's Disease 5.3 North America Alzheimer’s Therapeutics Market, by End-user (2021-2029) • Hospital Pharmacy • Retail Pharmacy • E-commerce 5.4 North America Alzheimer’s Therapeutics Market, by Country (2021-2029) • United States • Canada • Mexico 6. Europe Alzheimer’s Therapeutics Market (2021-2029) 6.1. European Alzheimer’s Therapeutics Market, by Therapeutics (2021-2029) 6.2. European Alzheimer’s Therapeutics Market, by Diagnostics (2021-2029) 6.3. European Alzheimer’s Therapeutics Market, by End-user (2021-2029) 6.4. European Alzheimer’s Therapeutics Market, by Country (2021-2029) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 7. Asia Pacific Alzheimer’s Therapeutics Market (2021-2029) 7.1. Asia Pacific Alzheimer’s Therapeutics Market, by Therapeutics (2021-2029) 7.2. Asia Pacific Alzheimer’s Therapeutics Market, by Diagnostics (2021-2029) 7.3. Asia Pacific Alzheimer’s Therapeutics Market, by End-user (2021-2029) 7.4. Asia Pacific Alzheimer’s Therapeutics Market, by Country (2021-2029) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 8. Middle East and Africa Alzheimer’s Therapeutics Market (2021-2029) 8.1 Middle East and Africa Alzheimer’s Therapeutics Market, by Therapeutics (2021-2029) 8.2. Middle East and Africa Alzheimer’s Therapeutics Market, by Diagnostics (2021-2029) 8.3. Middle East and Africa Alzheimer’s Therapeutics Market, by End-user (2021-2029) 8.4. Middle East and Africa Alzheimer’s Therapeutics Market, by Country (2021-2029) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 9. South America Alzheimer’s Therapeutics Market (2021-2029) 9.1. South America Alzheimer’s Therapeutics Market, by Therapeutics (2021-2029) 9.2. South America Alzheimer’s Therapeutics Market, by Diagnostics (2021-2029) 9.3. South America Alzheimer’s Therapeutics Market, by End-user (2021-2029) 9.4 South America Alzheimer’s Therapeutics Market, by Country (2021-2029) • Brazil • Argentina • Rest Of South America 10. Company Profile: Key players 10.1 Hoffmann-La Roche 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2 Novartis AG 10.3 Bristol-Myers Squibb 10.4 AstraZeneca PLC 10.5 Corium Inc. 10.6 Eisai Co. Ltd. 10.7 H. Lundbeck A/S 10.8 AC Immune 10.9 Biogen Inc. 10.10 Johnson & Johnson 10.11 Eli Lilly and Company 10.12 Lupin Limited 10.13 Daiichi Sankyo Company, Limited 10.14 TauRx Pharmaceuticals Ltd. 10.15 AbbVie Inc. 10.16 Siemens Healthineers 10.17 Zydus Cadila 10.18 Merz Pharma 10.19 Teva Pharmaceutical Industries Ltd 10.20 Adamas Pharmaceuticals Inc. 10.21 Aurobindo Pharma Ltd 10.22 Cipla Ltd. 10.23 Torrent pharmaceuticals ltd. 10.24 Lannett Inc. 10.25 Unichem laboratories ltd.

About This Report

Report ID 164747
Category Healthcare
Published Date Nov 2022
Updated Date
Contact Us